These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37328706)

  • 1. Concurrent chemoradiotherapy using proton beams can reduce cardiopulmonary morbidity in esophageal cancer patients: a systematic review.
    Nonaka T; Kawashiro S; Ishikawa H; Ito Y; Nemoto K; Ishihara R; Oyama T; Oyama T; Kato K; Kato H; Kawakubo H; Kawachi H; Kuribayashi S; Kono K; Kojima T; Takeuchi H; Tsushima T; Toh Y; Booka E; Makino T; Matsuda S; Matsubara H; Mano M; Minashi K; Miyazaki T; Muto M; Yamaji T; Yamatsuji T; Yoshida M; Kitagawa Y;
    Esophagus; 2023 Oct; 20(4):605-616. PubMed ID: 37328706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton beam therapy and concurrent chemotherapy for esophageal cancer.
    Lin SH; Komaki R; Liao Z; Wei C; Myles B; Guo X; Palmer M; Mohan R; Swisher SG; Hofstetter WL; Ajani JA; Cox JD
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e345-51. PubMed ID: 22417808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary treatment results of proton beam therapy with chemoradiotherapy for stage I-III esophageal cancer.
    Takada A; Nakamura T; Takayama K; Makita C; Suzuki M; Azami Y; Kato T; Tsukiyama I; Hareyama M; Kikuchi Y; Daimon T; Toyomasu Y; Ii N; Nomoto Y; Sakuma H; Fuwa N
    Cancer Med; 2016 Mar; 5(3):506-15. PubMed ID: 26806272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy.
    Shiraishi Y; Fang P; Xu C; Song J; Krishnan S; Koay EJ; Mehran RJ; Hofstetter WL; Blum-Murphy M; Ajani JA; Komaki R; Minsky B; Mohan R; Hsu CC; Hobbs BP; Lin SH
    Radiother Oncol; 2018 Jul; 128(1):154-160. PubMed ID: 29248170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis.
    Makishima H; Ishikawa H; Terunuma T; Hashimoto T; Yamanashi K; Sekiguchi T; Mizumoto M; Okumura T; Sakae T; Sakurai H
    J Radiat Res; 2015 May; 56(3):568-76. PubMed ID: 25755255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of lymphopenia during chemoradiotherapy using photons or protons on the clinical outcomes of esophageal cancer patients.
    Sumiya T; Ishikawa H; Hiroshima Y; Nakamura M; Murakami M; Mizumoto M; Okumura T; Sakurai H
    J Radiat Res; 2021 Oct; ():. PubMed ID: 34632514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Endoscopic Evaluation of Acute Radiation Esophagitis during Chemoradiotherapy with Proton Beam Therapy Boost for Esophageal Cancer.
    Hasatani K; Tamamura H; Yamamoto K; Aoyagi H; Miyanaga T; Kaizaki Y; Sawada T
    Digestion; 2020; 101(4):366-374. PubMed ID: 31067539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis.
    Xi M; Xu C; Liao Z; Chang JY; Gomez DR; Jeter M; Cox JD; Komaki R; Mehran R; Blum MA; Hofstetter WL; Maru DM; Bhutani MS; Lee JH; Weston B; Ajani JA; Lin SH
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(3):667-676. PubMed ID: 29280461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Comprehensive Analysis of Randomized Phase 2B Trial of Proton Beam Therapy Versus Intensity Modulated Radiation Therapy.
    Wang X; van Rossum PSN; Chu Y; Hobbs BP; Grassberger C; Hong TS; Liao Z; Yang J; Zhang X; Netherton T; Mohan R; Lin SH
    Int J Radiat Oncol Biol Phys; 2024 Feb; 118(2):368-377. PubMed ID: 37652304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis.
    Dutz A; Agolli L; Baumann M; Troost EGC; Krause M; Hölscher T; Löck S
    Acta Oncol; 2019 Jun; 58(6):916-925. PubMed ID: 30882264
    [No Abstract]   [Full Text] [Related]  

  • 11. Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma.
    Hirano Y; Onozawa M; Hojo H; Motegi A; Zenda S; Hotta K; Moriya S; Tachibana H; Nakamura N; Kojima T; Akimoto T
    Radiat Oncol; 2018 Feb; 13(1):23. PubMed ID: 29426342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy.
    Shiraishi Y; Xu C; Yang J; Komaki R; Lin SH
    Radiother Oncol; 2017 Oct; 125(1):48-54. PubMed ID: 28917586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton beam therapy reduces the risk of severe radiation-induced lymphopenia during chemoradiotherapy for locally advanced non-small cell lung cancer: A comparative analysis of proton versus photon therapy.
    Kim N; Myoung Noh J; Lee W; Park B; Park H; Young Park J; Pyo H
    Radiother Oncol; 2021 Mar; 156():166-173. PubMed ID: 33359267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review.
    Verma V; Lin SH; Simone CB; Mehta MP
    J Gastrointest Oncol; 2016 Aug; 7(4):644-64. PubMed ID: 27563457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathologic complete response (pCR) rates and outcomes after neoadjuvant chemoradiotherapy with proton or photon radiation for adenocarcinomas of the esophagus and gastroesophageal junction.
    DeCesaris CM; Berger M; Choi JI; Carr SR; Burrows WM; Regine WF; Simone CB; Molitoris JK
    J Gastrointest Oncol; 2020 Aug; 11(4):663-673. PubMed ID: 32953150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing 90-Day Postoperative Mortality After Neoadjuvant Proton-Based Versus Photon-Based Chemoradiotherapy for Esophageal Cancer.
    Damen PJJ; van Rossum PSN; Chen Y; Abana CO; Liao Z; Hobbs BP; Mohan R; Blum-Murphy M; Hofstetter WL; Lin SH
    Int J Part Ther; 2024 Mar; 11():100012. PubMed ID: 38757082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Promise of Proton Beam Therapy for Oesophageal Cancer: A Systematic Review of Dosimetric and Clinical Outcomes.
    Nicholas O; Prosser S; Mortensen HR; Radhakrishna G; Hawkins MA; Gwynne SH
    Clin Oncol (R Coll Radiol); 2021 Aug; 33(8):e339-e358. PubMed ID: 33931290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Proton beam therapy with concurrent chemotherapy for non-small cell lung cancer -- our experiences and future direction].
    Niho S; Motegi A; Akimoto T
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):144-7. PubMed ID: 25743132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness of Proton vs Photon Therapy as Part of Concurrent Chemoradiotherapy for Locally Advanced Cancer.
    Baumann BC; Mitra N; Harton JG; Xiao Y; Wojcieszynski AP; Gabriel PE; Zhong H; Geng H; Doucette A; Wei J; O'Dwyer PJ; Bekelman JE; Metz JM
    JAMA Oncol; 2020 Feb; 6(2):237-246. PubMed ID: 31876914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of intensity-modulated proton therapy in reducing radiation-induced lymphopenia in glioma patients.
    Das A; Sylvia J; Krishnan G; Panda PK; Subramanyam P; Kumar R; Adhithyan R; Patil S; Sharma D; Jalali R
    Neurooncol Adv; 2024; 6(1):vdae088. PubMed ID: 39045310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.